Vaxart (NASDAQ:VXRT) Stock Price Crosses Below 200 Day Moving Average of $2.27

Vaxart, Inc. (NASDAQ:VXRTGet Rating) shares passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $2.27 and traded as low as $1.08. Vaxart shares last traded at $1.13, with a volume of 1,450,142 shares trading hands.

Wall Street Analysts Forecast Growth

VXRT has been the subject of several recent analyst reports. B. Riley decreased their price target on Vaxart from $6.00 to $1.50 and set a “neutral” rating for the company in a research note on Monday, December 19th. Brookline Capital Management reissued a “buy” rating on shares of Vaxart in a research report on Monday, October 3rd.

Vaxart Stock Up 6.6 %

The company has a market cap of $148.31 million, a PE ratio of -1.36 and a beta of 0.78. The company’s fifty day moving average is $1.12 and its 200-day moving average is $2.27.

Vaxart (NASDAQ:VXRTGet Rating) last released its quarterly earnings results on Tuesday, November 8th. The biotechnology company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.01. Equities research analysts expect that Vaxart, Inc. will post -0.84 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of VXRT. Two Sigma Advisers LP bought a new position in shares of Vaxart in the 3rd quarter worth approximately $34,000. Y Intercept Hong Kong Ltd purchased a new stake in Vaxart during the second quarter valued at approximately $37,000. Beacon Capital Management LLC increased its holdings in Vaxart by 116.3% during the third quarter. Beacon Capital Management LLC now owns 10,814 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 5,814 shares during the last quarter. Atom Investors LP bought a new position in Vaxart in the third quarter worth approximately $39,000. Finally, Moors & Cabot Inc. boosted its stake in shares of Vaxart by 100.0% during the 3rd quarter. Moors & Cabot Inc. now owns 20,000 shares of the biotechnology company’s stock worth $44,000 after acquiring an additional 10,000 shares during the last quarter. 38.66% of the stock is owned by hedge funds and other institutional investors.

About Vaxart

(Get Rating)

Vaxart, Inc, a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection.

Featured Stories

Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with's FREE daily email newsletter.